Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmacovigilance Outsourcing Market

5.1. COVID-19 Landscape: Pharmacovigilance Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmacovigilance Outsourcing Market, By Service

8.1. Pharmacovigilance Outsourcing Market, by Service, 2024-2033

8.1.1. Pre-marketing Pharmacovigilance Services

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Post-marketing Pharmacovigilance Services

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Pharmacovigilance Outsourcing Market, By Service Providers

9.1. Pharmacovigilance Outsourcing Market, by Service Providers, 2024-2033

9.1.1. Contract Research Organizations (CROs)

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Business Processing Outsourcing (BPO)

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Pharmacovigilance Outsourcing Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Service (2021-2033)

10.1.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Service (2021-2033)

10.2.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Service (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Service (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Service (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Service (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Service (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Service (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Service (2021-2033)

10.5.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Service (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Service Providers (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Service (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Service Providers (2021-2033)

Chapter 11. Company Profiles

11.1. Labcorp Drug Development

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Icon Plc

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Cognizant Technology Solutions Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Ergomed Plc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Capgemini

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Genpact Limited

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Accenture Plc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Iqvia Holdings Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. International Business Machines Corporation

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Bioclinica Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms